TW201738221A - 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用 - Google Patents

新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用 Download PDF

Info

Publication number
TW201738221A
TW201738221A TW106113369A TW106113369A TW201738221A TW 201738221 A TW201738221 A TW 201738221A TW 106113369 A TW106113369 A TW 106113369A TW 106113369 A TW106113369 A TW 106113369A TW 201738221 A TW201738221 A TW 201738221A
Authority
TW
Taiwan
Prior art keywords
group
aryl
heteroaryl
cycloalkyl
alkyl
Prior art date
Application number
TW106113369A
Other languages
English (en)
Chinese (zh)
Inventor
Yan Xia
Min Han
Wei Li
Yang Chu
gui-rong Bai
wen-li Tian
Ju Li
Wei Zhou
Guo-Cheng Wang
Yi He
xiao-hui Ma
shui-ping Zhou
He Sun
Original Assignee
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Tasly Diyi Pharmaceutical Co Ltd filed Critical Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Publication of TW201738221A publication Critical patent/TW201738221A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW106113369A 2016-04-22 2017-04-21 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用 TW201738221A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610257993 2016-04-22

Publications (1)

Publication Number Publication Date
TW201738221A true TW201738221A (zh) 2017-11-01

Family

ID=60115718

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106113369A TW201738221A (zh) 2016-04-22 2017-04-21 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用

Country Status (3)

Country Link
CN (1) CN107304200B (fr)
TW (1) TW201738221A (fr)
WO (1) WO2017181993A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110559294A (zh) * 2018-06-06 2019-12-13 杨仑 脂肪性肝病及其相关疾病的预防和治疗性药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7304078B2 (en) * 2002-04-16 2007-12-04 Schering Corporation Thrombin receptor antagonists
EP1971336A2 (fr) * 2005-12-22 2008-09-24 Shering Corporation Antagonistes de recepteur de thrombine en tant que phophylaxie aux complications de derivation cardiopulmonaire
WO2009124103A2 (fr) * 2008-04-02 2009-10-08 Schering Corporation Thérapies de combinaison comprenant des antagonistes de récepteur 1 activé par protéase (par1) associés à des antagonistes récepteur 4 activé par protéase (par4)
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Also Published As

Publication number Publication date
CN107304200B (zh) 2021-09-21
CN107304200A (zh) 2017-10-31
WO2017181993A1 (fr) 2017-10-26

Similar Documents

Publication Publication Date Title
JP4860698B2 (ja) 因子Ｘａ阻害剤としての新規なシクロアルカンカルボキシアミド
JP2021523887A (ja) ＸＩＩａ因子インヒビター
JP2021519766A (ja) ＸＩＩａ因子インヒビター
JP6670913B2 (ja) 白血病を予防および治療するためのマレイミド誘導体の使用
JPH08169884A (ja) シクロプロパクロメンカルボン酸誘導体
CA3152508A1 (fr) Composes de pyrrolopyrimidine inhibiteurs de perk
TW202003472A (zh) 鈣蛋白酶(calpain)調節劑及其醫療用途
TW201713623A (zh) １，２，３，４－四氫異喹啉衍生物、其製備方法和應用
KR20220068224A (ko) Perk 억제 화합물
KR20170066609A (ko) 인돌리논 화합물 및 이의 용도
TW202341987A (zh) 一種Polθ抑制劑
JP2015083610A (ja) 疼痛および他の疾患の処置のための化合物および方法
JP2025081626A (ja) ペンタミジンの類似体及びその使用
JP6407257B2 (ja) アルキニルインダゾール誘導体及びその用途
AU2014214324B2 (en) Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4
CN112778273B (zh) 环酮并吡啶酮类化合物及其制备方法和用途
TW201400458A (zh) （２－雜芳基胺基）琥珀酸衍生物
CN107304200B (zh) 一种新的喜巴辛类似物及其在医药中的应用
CN105324382B (zh) 4,5‑二氢吡唑并[3,4‑c]吡啶‑2‑酮的螺环衍生物、其制备方法以及应用
CN107304199B (zh) 一种新的喜巴辛类似物及其在医药中的应用
CN111247148B (zh) Wnt通路调节剂
JP2007262022A (ja) 新規２−チオフェンカルボキサミド誘導体
KR102649886B1 (ko) 신규한 피리미딘-4-온 화합물 및 이를 포함하는 항암제 조성물
WO2014043895A1 (fr) Dérivé 2-hydroxyl tétrahydro thiénopyridine doté d'une activité optique et procédé de préparation et utilisation associés
CN102199150A (zh) 光学活性噁唑烷酮类衍生物及其制备方法与在制药中的用途